The Motley Fool

This small-cap ASX biotech’s share price is soaring today

The Medlab Clinical Ltd (ASX: MDC) share price is up 7.1% to $0.38 in Thursday trade following the release of an operations update this morning. The company announced that it had delivered a very strong June quarter, with progress being made in its research-driven development along with a significant improvement in the commercialisation of its products. 

For the June quarter, Medlab reported total revenue in excess of $3 million (excluding R&D incentive and after discounts). This was an increase of 135% over the same quarter last year. Furthermore, the company has achieved year on year growth in excess of 50% (excluding R&D incentive and after discounts). 

A closer look at Medlab Clinical

Medlab Clinical is a medical life science company that is developing therapeutic pathways for diagnosed chronic diseases. The company is developing therapies for pain management, depression and obesity in conjunction with earning revenue from the sale of nutritional products in Australia and the United States (US). Of particular note is Medlab’s focus on developing cannabis-based medicines for pain management.

During the June quarter, Medlab implemented its rollout and placement for its self-branded nutraceutical range products into Priceline and Terry White Chemmart pharmacies. Medlab’s range of products can now be found in more than 3,000 pharmacies in Australia. 

Medical cannabis presents growth opportunity

Regarding medical cannabis, the company is actively pursuing regulatory pathways via the Therapeutic Goods Association (TGA) in Australia, Food and Drug Administration (FDA) in the United States and the European Medicine Agency. The core long-term objective remains to achieve a research-backed registered drug in major global markets. 

Research into Medlab’s patented cannabis-based medicine NanaBis continues to progress well. The company has also entered into a number of agreements with multinational partners. In March, a heads of agreement was executed with Canadian pharmaceutical company Pharmascience Inc. for further development and distribution of NanaBis. In May, Medlab executed a heads of agreement with Thai pharmaceutical company Mega Lifesciences Public Company Limited for the distribution of NanaBis in parts of South America. 

Other cannabis stocks such as AusCann Group Holdings Ltd (ASX: AC8) and Creso Pharma Ltd (ASX: CPH) have also risen 4.2% and 1.0%, respectively, in Thursday trade. 

Investors interested in the cannabis space may also want to check out this buy-rated stock

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more

Motley Fool contributor Tim Katavic has no financial interest in any company mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

CLICK HERE FOR YOUR FREE REPORT!